Hyperbaric Oxygen Therapy - Hyperbaric Chamber Information ...

Clinical need
Brief prevalence data for some of the indications examined in this report are shown in
Table 1. No reliable Australian estimates are available for Fournier’s gangrene,
necrotising arachnidism, osteoradionecrosis, acute ankle sprains, sudden deafness and
acoustic trauma, radionecrosis, cerebral palsy, Crohn’s disease, and Legg-Calve-Perthes
disease.
Table 1 Measures of disease burden for selected conditions.
Condition
Hospital
Separations
Deaths Years of
Potential Life
Lost
Thermal burns 6,063 *# 34 † 609 † 5, 6
Diabetic foot
Amputations**
972 ‡#
2,800 §#
Non-diabetic wounds 780 ‡# 7
Necrotising fasciitis 108 ‡# 7
Actinomycosis 174 ‡# 7
Problem Wounds
Osteomyelitis
Skin grafts
Cardiovascular disease conditions
Acute myocardial infarction
Cerebrovascular disease
Peripheral obstructive arterial disease
2,225 ‡#
35,780 ‡#
28,632 ‡#
24,976 ‡#
29,051 §#
12,133 §#
411 †
65,448 †
24,114 †
2,528 †
Crush injuries 1,153 ‡# 7
Multiple sclerosis 36 † 586 † 6
Cluster and migraine headaches 16,015 ‡# 7
Facial paralysis 654 ‡# 7
Osteoporosis 24 † 146 † 6
Carbon monoxide poisoning 568 ‡# 7
References
* 1995-1996 data.
† 1996 data.
‡ 1997-1998 data.
§ 1997 data
# National estimates
Victorian estimates
** Prevalence estimated as 25 per 1,000 population. Incidence estimated as 1.1 per 1,000 population. Both figures are 1998 national
rates. (Colagiuri S, Colagiuri R, Ward J. National Diabetes Strategy and Implemenation Plan. Canberra: Diabetes Australia, 1998.)
Existing procedures and comparators
In this review, exposure to HBO is compared to procedures not using HBO, including
standard or conventional therapy (variously defined), normobaric oxygen, or placebo
procedures. The effectiveness of one HBOT protocol against another is not examined.
4 Hyperbaric oxygen therapy
7
7
7
6-8
6-8
6